{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TDF%2FFTC&page=2", "query": { "intervention": "TDF/FTC", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TDF%2FFTC&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-04T23:03:21.753Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03711253", "title": "Empiric Treatment for Acute HIV in the ED", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute HIV Infection" ], "interventions": [ { "name": "Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2019-10-14", "completion_date": "2023-06-01", "has_results": false, "last_update_posted_date": "2023-04-26", "last_synced_at": "2026-09-04T23:03:21.753Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03711253" }, { "nct_id": "NCT01475838", "title": "Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "PI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "Stribild", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 438, "start_date": "2011-11", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-06-08", "last_synced_at": "2026-09-04T23:03:21.753Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Hayward, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01475838" }, { "nct_id": "NCT03060785", "title": "Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Prevention" ], "interventions": [ { "name": "Tenofovir Disoproxil Fumarate/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 16, "start_date": "2016-03-08", "completion_date": "2018-05-31", "has_results": false, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-09-04T23:03:21.753Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03060785" }, { "nct_id": "NCT02616029", "title": "Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2015-12-17", "completion_date": "2019-07-11", "has_results": true, "last_update_posted_date": "2020-07-23", "last_synced_at": "2026-09-04T23:03:21.753Z", "location_count": 3, "location_summary": "Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida", "locations": [ { "city": "Ft. Pierce", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02616029" }, { "nct_id": "NCT03512964", "title": "Rapid HIV Treatment Initiation, Access and Engagement in Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Human Immunodeficiency Virus" ], "interventions": [ { "name": "Dolutegravir 50 MG", "type": "DRUG" }, { "name": "Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2016-11-29", "completion_date": "2020-09-13", "has_results": true, "last_update_posted_date": "2022-10-27", "last_synced_at": "2026-09-04T23:03:21.753Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03512964" }, { "nct_id": "NCT02607956", "title": "Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "DTG", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "DTG Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 657, "start_date": "2015-11-11", "completion_date": "2021-07-05", "has_results": true, "last_update_posted_date": "2022-03-07", "last_synced_at": "2026-09-04T23:03:21.753Z", "location_count": 74, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 53 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607956" }, { "nct_id": "NCT00768989", "title": "Phase IIB Pilot of Atazanavir + Raltegravir", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 167, "start_date": "2008-11", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2012-02-24", "last_synced_at": "2026-09-04T23:03:21.753Z", "location_count": 9, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00768989" }, { "nct_id": "NCT03126370", "title": "Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C", "HIV Coinfection" ], "interventions": [ { "name": "TDF with a boosted protease inhibitor", "type": "DRUG" }, { "name": "TAF with a boosted protease inhibitor", "type": "DRUG" }, { "name": "TAF with a boosted protease inhibitor and LDV/SOF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2018-01-08", "completion_date": "2019-10-01", "has_results": true, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-09-04T23:03:21.753Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126370" }, { "nct_id": "NCT03717129", "title": "Analysis of Crushed and Whole Tablet Genvoya", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Genvoya Oral dose", "type": "DRUG" }, { "name": "Genvoya Crushed Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2019-04-15", "completion_date": "2021-11-01", "has_results": true, "last_update_posted_date": "2023-01-31", "last_synced_at": "2026-09-04T23:03:21.753Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03717129" }, { "nct_id": "NCT05108935", "title": "Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Opioid Use", "Opioid Use Disorder", "Risk Reduction", "Hiv", "Hepatitis C" ], "interventions": [ { "name": "Suboxone", "type": "DRUG" }, { "name": "Truvada", "type": "DRUG" }, { "name": "Mavyret", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2022-02-17", "completion_date": "2023-03-30", "has_results": false, "last_update_posted_date": "2023-04-27", "last_synced_at": "2026-09-04T23:03:21.753Z", "location_count": 2, "location_summary": "Durham, North Carolina • Greensboro, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Greensboro", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05108935" } ] }